ES2204967T5 - Vacuna combinada de la meningitis. - Google Patents
Vacuna combinada de la meningitis. Download PDFInfo
- Publication number
- ES2204967T5 ES2204967T5 ES95935550T ES95935550T ES2204967T5 ES 2204967 T5 ES2204967 T5 ES 2204967T5 ES 95935550 T ES95935550 T ES 95935550T ES 95935550 T ES95935550 T ES 95935550T ES 2204967 T5 ES2204967 T5 ES 2204967T5
- Authority
- ES
- Spain
- Prior art keywords
- vaccine
- hib
- oligosaccharides
- vaccine according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 60
- 201000009906 Meningitis Diseases 0.000 title claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 33
- 150000002482 oligosaccharides Chemical class 0.000 claims description 32
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 229940032024 DPT vaccine Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960000814 tetanus toxoid Drugs 0.000 claims description 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 101710116435 Outer membrane protein Proteins 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 abstract description 4
- 201000009904 bacterial meningitis Diseases 0.000 abstract description 4
- 101000604746 Arabidopsis thaliana 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 description 21
- 206010013023 diphtheria Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108010060123 Conjugate Vaccines Proteins 0.000 description 10
- 229940031670 conjugate vaccine Drugs 0.000 description 10
- 108010078791 Carrier Proteins Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 241000606768 Haemophilus influenzae Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010043376 Tetanus Diseases 0.000 description 5
- 229940001442 combination vaccine Drugs 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000116710 Ferula foetidissima Species 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- -1 amino oligosaccharides Chemical class 0.000 description 2
- 230000002096 anti-tetanic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000023445 Congenital pulmonary airway malformation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422096A GB9422096D0 (en) | 1994-11-02 | 1994-11-02 | Combined meningitis vaccine |
| GB9422096 | 1994-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2204967T3 ES2204967T3 (es) | 2004-05-01 |
| ES2204967T5 true ES2204967T5 (es) | 2008-07-01 |
Family
ID=10763774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95935550T Expired - Lifetime ES2204967T5 (es) | 1994-11-02 | 1995-11-02 | Vacuna combinada de la meningitis. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6251401B1 (OSRAM) |
| EP (3) | EP2204185A1 (OSRAM) |
| JP (3) | JP3989951B2 (OSRAM) |
| AT (1) | ATE246936T1 (OSRAM) |
| CA (2) | CA2689871A1 (OSRAM) |
| CY (1) | CY2423B1 (OSRAM) |
| DE (1) | DE69531501T3 (OSRAM) |
| DK (1) | DK0789587T4 (OSRAM) |
| ES (1) | ES2204967T5 (OSRAM) |
| GB (1) | GB9422096D0 (OSRAM) |
| PT (1) | PT789587E (OSRAM) |
| WO (1) | WO1996014086A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US6048527A (en) * | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
| ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
| JP2002508748A (ja) * | 1997-05-01 | 2002-03-19 | カイロン コーポレイション | アジュバントとしてのウイルス様粒子の使用 |
| EP0983342B1 (en) * | 1997-05-28 | 2007-09-05 | Novartis Vaccines and Diagnostics S.r.l. | Culture medium with soy bean extract as aminoacid source and no protein complexes of animal origin |
| US20040087020A1 (en) | 1997-05-28 | 2004-05-06 | Chiron S.P.A. | Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin |
| US20070259007A1 (en) * | 1999-10-19 | 2007-11-08 | Kruzel Marian L | Lactoferrin: an adjuvant for vaccines |
| DK1233784T3 (da) * | 1999-12-02 | 2008-09-01 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| KR100898845B1 (ko) * | 2000-06-29 | 2009-05-21 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 다가 백신 조성물 |
| US7534444B2 (en) | 2001-04-17 | 2009-05-19 | Novattis Vaccines And Diagnostics, Inc. | Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| MXPA04011249A (es) * | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| JP4827726B2 (ja) | 2003-01-30 | 2011-11-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群に対する注射可能ワクチン |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| ES2397923T3 (es) | 2003-10-02 | 2013-03-12 | Novartis Ag | Vacunas líquidas para múltiples serogrupos meningocócicos |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| KR101359953B1 (ko) * | 2005-06-27 | 2014-02-21 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| WO2008149238A2 (en) * | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
| EP2462949A3 (en) * | 2007-10-19 | 2012-09-05 | Novartis AG | Meningococcal vaccine formulations |
| WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
| DK2608805T4 (da) | 2010-08-23 | 2025-06-30 | Wyeth Llc | STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER |
| RU2546873C2 (ru) | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| PE20190458A1 (es) | 2012-03-09 | 2019-04-01 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| MX391027B (es) | 2015-02-19 | 2025-03-21 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| CN115605222A (zh) | 2019-09-27 | 2023-01-13 | 辉瑞公司（Us） | 脑膜炎奈瑟氏菌组合物及其方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4451446A (en) | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5371197A (en) * | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US5628496A (en) | 1995-06-07 | 1997-05-13 | Avm, Inc. | Pneumatic spring |
| US6048527A (en) * | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
-
1994
- 1994-11-02 GB GB9422096A patent/GB9422096D0/en active Pending
-
1995
- 1995-11-02 US US08/836,080 patent/US6251401B1/en not_active Expired - Lifetime
- 1995-11-02 ES ES95935550T patent/ES2204967T5/es not_active Expired - Lifetime
- 1995-11-02 CA CA2689871A patent/CA2689871A1/en not_active Abandoned
- 1995-11-02 DE DE69531501T patent/DE69531501T3/de not_active Expired - Lifetime
- 1995-11-02 WO PCT/IB1995/001006 patent/WO1996014086A1/en not_active Ceased
- 1995-11-02 CA CA002204277A patent/CA2204277C/en not_active Expired - Fee Related
- 1995-11-02 EP EP10075114A patent/EP2204185A1/en not_active Withdrawn
- 1995-11-02 PT PT95935550T patent/PT789587E/pt unknown
- 1995-11-02 JP JP51517596A patent/JP3989951B2/ja not_active Expired - Fee Related
- 1995-11-02 AT AT95935550T patent/ATE246936T1/de active
- 1995-11-02 DK DK95935550T patent/DK0789587T4/da active
- 1995-11-02 EP EP95935550A patent/EP0789587B2/en not_active Expired - Lifetime
- 1995-11-02 EP EP03075069A patent/EP1312377A3/en not_active Withdrawn
-
2004
- 2004-01-30 CY CY0400008A patent/CY2423B1/xx unknown
-
2007
- 2007-03-27 JP JP2007083117A patent/JP4871770B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-21 JP JP2010236921A patent/JP2011016850A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1312377A2 (en) | 2003-05-21 |
| EP2204185A1 (en) | 2010-07-07 |
| WO1996014086A1 (en) | 1996-05-17 |
| EP2204185A8 (en) | 2010-10-27 |
| DE69531501T2 (de) | 2004-06-24 |
| EP0789587B1 (en) | 2003-08-13 |
| JP4871770B2 (ja) | 2012-02-08 |
| DE69531501T3 (de) | 2008-11-13 |
| DK0789587T3 (da) | 2003-12-01 |
| US6251401B1 (en) | 2001-06-26 |
| CA2204277A1 (en) | 1996-05-17 |
| EP0789587A1 (en) | 1997-08-20 |
| CA2204277C (en) | 2010-02-02 |
| JPH10509701A (ja) | 1998-09-22 |
| JP3989951B2 (ja) | 2007-10-10 |
| DK0789587T4 (da) | 2008-08-04 |
| CA2689871A1 (en) | 1996-05-17 |
| GB9422096D0 (en) | 1994-12-21 |
| CY2423B1 (en) | 2004-11-12 |
| ES2204967T3 (es) | 2004-05-01 |
| PT789587E (pt) | 2003-12-31 |
| JP2007169302A (ja) | 2007-07-05 |
| DE69531501D1 (de) | 2003-09-18 |
| ATE246936T1 (de) | 2003-08-15 |
| EP1312377A3 (en) | 2004-02-04 |
| JP2011016850A (ja) | 2011-01-27 |
| EP0789587B2 (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2204967T5 (es) | Vacuna combinada de la meningitis. | |
| Frasch | Vaccines for prevention of meningococcal disease | |
| FERRECCIO et al. | The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age | |
| Anderson et al. | Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults | |
| Eskola et al. | Pneumococcal conjugate vaccines | |
| Cohen et al. | Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers | |
| Peltola et al. | Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides | |
| ÅHMAN et al. | Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants | |
| Einhorn et al. | Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein | |
| Gold et al. | Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children | |
| Lepow et al. | Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age | |
| CA2264735C (en) | Neisseria meningitidis serogroup b glycoconjugates and methods of using the same | |
| Austrian | Pneumococcal polysaccharide vaccines | |
| Ahonkhai et al. | Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate)(PedvaxHIBTM): clinical evaluation | |
| Vella et al. | Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (Meningococcal protein conjugate)(PedvaxHIBTM) | |
| Devi et al. | Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys | |
| PL174130B1 (pl) | Złożona szczepionka pediatryczna przeciwko błonicy, tężcowi, ksztuścowi oraz Haemophilus influenzae typu b | |
| Wahdan et al. | Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2 | |
| Jang et al. | Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine | |
| MULHOLLAND et al. | Safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheriatetanus-pertussis vaccine in young Gambian infants | |
| Panpitpat et al. | Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine | |
| Eskola | Analysis Of Haemophilus Infiuenzae Type B Conjugate And Diphtheria-Tetanuspertussis Combination Vaccines | |
| Decker et al. | The multicenter acellular pertussis trial: an overview | |
| Steinhoff et al. | Group C Neisseria meningitidis variant polysaccharide vaccines in children | |
| Knutsson et al. | Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine |